Some Type 2 Drugs Could Cut Risk of Kidney Disease
The glucose-lowering drugs canagliflozin (Invokana) and dapagliflozin (Farxiga) could cut kidney disease risks in people with type 2 diabetes, according to two studies. The first looked at 4,401 people with type 2 and chronic kidney disease. After about 2½ years, the combined risk for worsening kidney disease, death due to kidney disease, and kidney failure was 30 percent lower with canagliflozin compared with a placebo. In the other study, researchers followed 17,160 people with type 2 diabetes—most of whom had normal kidney function but were at high risk for heart disease—for four years. Compared with a placebo, dapagliflozin cut kidney disease risks by 47 percent. Both drugs have side effects, including increased risk for genital infections, so discuss with your doctor whether one of them might be right for you.
Sources: The New England Journal of Medicine, published online June 13, 2019; The Lancet Diabetes and Endocrinology, published online June 9, 2019